Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Enanta Pharmaceuticals (ENTA) Non Operating Income (2016 - 2025)

Enanta Pharmaceuticals' Non Operating Income history spans 14 years, with the latest figure at -$661000.0 for Q4 2025.

  • For Q4 2025, Non Operating Income fell 178.97% year-over-year to -$661000.0; the TTM value through Dec 2025 reached $302000.0, down 92.22%, while the annual FY2025 figure was $1.8 million, 53.88% down from the prior year.
  • Non Operating Income reached -$661000.0 in Q4 2025 per ENTA's latest filing, down from -$282000.0 in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $1.9 million in Q2 2023 to a low of -$661000.0 in Q4 2025.
  • Average Non Operating Income over 5 years is $709550.0, with a median of $667500.0 recorded in 2024.
  • Peak YoY movement for Non Operating Income: soared 620.39% in 2023, then plummeted 178.97% in 2025.
  • A 5-year view of Non Operating Income shows it stood at $258000.0 in 2021, then soared by 284.88% to $993000.0 in 2022, then dropped by 13.7% to $857000.0 in 2023, then dropped by 2.33% to $837000.0 in 2024, then tumbled by 178.97% to -$661000.0 in 2025.
  • Per Business Quant, the three most recent readings for ENTA's Non Operating Income are -$661000.0 (Q4 2025), -$282000.0 (Q3 2025), and $667000.0 (Q2 2025).